ENDRA Life Sciences Inc (NDRA)

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Form 425 - Prospectuses and communications, business combinations

ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing

Combination, if successful, would establish Noble Africa as a Nasdaq-listed, helium platform for Renergen’s Virginia Gas Project Listing expected...

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing

Combination, if successful, would establish Noble Africa as a Nasdaq-listed, helium platform for Renergen’s...

Form 8-K - Current report

Form RW - Registration Withdrawal Request

ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility

Results confirm accurate and consistent liver steatosis assessment performance across operators, geographies and patient populations, supporting...

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]